| Naslov: | Vericiguat Therapy Is Associated with Reverse Myocardial Remodeling in Chronic Heart Failure with Reduced Ejection Fraction |
|---|
| Avtorji: | ID Bajec, Tine (Avtor)
ID Žorž, Neža (Avtor)
ID Ugovšek, Sabina (Avtor)
ID Zemljič, Gregor (Avtor)
ID Cerar, Andraž (Avtor)
ID Frljak, Sabina (Avtor)
ID Okrajšek, Renata (Avtor)
ID Girandon Sušanj, Petra (Avtor)
ID Šebeštjen, Miran (Avtor)
ID Vrtovec, Bojan (Avtor)
ID Poglajen, Gregor (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (1,27 MB)
MD5: 14DAD04C8F967631F79B9859BF5C5D4A
 URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2308-3425/13/1/17
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | Background and aims: Vericiguat lowers cardiovascular death or heart-failure hospitalization in recently worsened heart failure with reduced ejection fraction (HFrEF), but its effects on cardiac remodeling are less well characterized. Our aim was to evaluate whether the addition of vericiguat to guideline-directed medical therapy (GDMT) promotes reverse myocardial remodeling in patients with HFrEF and recent worsening. Methods: We conducted a prospective, non-randomized, single-center study enrolling 34 consecutive patients with HFrEF who had experienced recent worsening and were on stable GDMT for at least 3 months prior to decompensation. Clinical, biochemical, and echocardiographic assessments were performed at baseline and at 6 months. Results: A total of 24 patients completed the 6-month follow-up (mean age 63 ± 9 years; 92% male), 96% of whom were in New York Heart Association (NYHA) class III or IV. After 6 months of vericiguat therapy, right ventricular systolic function improved significantly, with an increase in tricuspid annular plane systolic excursion (TAPSE) from 18.5 ± 4.3 mm to 21.4 ± 4.8 mm (p = 0.003). Left ventricular systolic function improved, with a numerical increase in left ventricular ejection fraction (LVEF) (30.1 ± 5.9% to 32.2 ± 10.5%; p = 0.122) and a significant increase in left ventricular outflow tract velocity-time integral (LVOT VTI) (14.8 ± 3.7 cm to 16.1 ± 3.8 cm; p = 0.011). Functional improvements were accompanied by structural remodeling, including reductions in right ventricular internal diameter in diastole (RVIDd) (40.5 ± 5.8 mm to 37.9 ± 6.9 mm; p = 0.002) and left ventricular end-systolic volume (LVESV) (144.0 ± 40.3 mL to 132.4 ± 61.0 mL; p = 0.031). N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels also decreased significantly (median 1829.0 ng/mL to 1241.0 ng/mL; p = 0.03). Conclusions: In patients with HFrEF and recent worsening, the addition of vericiguat to GDMT may be associated with reverse myocardial remodeling. |
|---|
| Ključne besede: | heart failure, myocardial reverse remodeling, soluble guanylate cyclase stimulator |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Leto izida: | 2026 |
|---|
| Št. strani: | str. 1-15 |
|---|
| Številčenje: | Vol. 13, iss. 1, [article no.] 17 |
|---|
| PID: | 20.500.12556/DiRROS-27692  |
|---|
| UDK: | 616.1 |
|---|
| ISSN pri članku: | 2308-3425 |
|---|
| DOI: | 10.3390/jcdd13010017 |
|---|
| COBISS.SI-ID: | 268104195 |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 11. 2. 2026;
|
|---|
| Datum objave v DiRROS: | 19.02.2026 |
|---|
| Število ogledov: | 315 |
|---|
| Število prenosov: | 162 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
